Sex-specific bone mass regulation by the X-linked gene KDM5C
Official title: Sexually dimorphic regulation of bone mass by the X-linked histone modifier KDM5C
Funded at Van Andel Research Institute · NIH-11349761 · Data updated 2026-11-12
A researcher team is studying how the X-linked enzyme KDM5C influences bone mass in women, aiming to understand why osteoporosis risk differs by sex and how this pathway could be targeted in the future.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Van Andel Research Institute NIH-funded |
| Lab location | 1 site (Grand Rapids, United States) |
| Project start | August 19, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $620,093 |
| NIH project number | 5R01AR084693-03 |
| Project ID | NIH-11349761 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals at risk for osteoporosis or with bone loss, particularly women, could benefit from future therapies arising from this research.
✕Less likely to help
The study is basic/mechanistic and does not involve patient participation; direct benefits to participants are not anticipated in the current plan.
What this research studies
This project will explore how losing KDM5C affects osteoclasts, bone cells that break down bone, and how these cells talk to osteoblasts that build bone. The team will map the epigenetic and genetic changes caused by KDM5C in bone- related cells and study how energy use in osteoclasts impacts bone loss with age or disease. Findings could point to new strategies to prevent osteoporosis in women by targeting this X-linked regulator.
Why it matters
Potential benefit: If successful, the work could lead to new approaches to prevent or treat osteoporosis, especially in women, by targeting KDM5C-related pathways.
How similar studies have gone: Preclinical studies in bone biology have shown that epigenetic regulators can modulate osteoclast function and bone mass, supporting a translational potential for this approach.
Where this research is happening
-
Van Andel Research Institute
Grand Rapids, United States Active
Researchers
- Principal investigator: Yang, Tao — Van Andel Research Institute
- Study coordinator: Yang, Tao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.